et al . et al . et al . et al . et al .
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
EDITORIAL

Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia’s role

Suzanne M. Garland A B C D H , Julia M. L. Brotherton E , Christopher K. Fairley F G , Dorota M. Gertig E and Marion Saville E

A Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Locked Bag 300, Parkville, Vic. 3052, Australia.

B Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Vic. 3052, Australia.

C Murdoch Childrens Research Institute, University of Melbourne, Parkville, Vic. 3052, Australia.

D Department of Microbiology, Royal Children’s Hospital, Parkville, Vic. 3052, Australia.

E Victorian Cytology Service, PO Box 161, Carlton South, Vic. 3053, Australia.

F School of Population Health, University of Melbourne, Carlton, Vic. 3053, Australia.

G Melbourne Sexual Health Centre, 580 Swanston Street, Carlton, Vic. 3053, Australia.

H Corresponding author. Email: Suzanne.garland@thewomens.org.au

Sexual Health 7(3) 227-229 http://dx.doi.org/10.1071/SH10088
Submitted: 20 July 2010  Accepted: 26 July 2010   Published: 19 August 2010


References

[1]  Rigoni-Stern D 1842 Fatti statistici relativi alle malattic cancerose. Giorn Prog Patol Terap 2 507 17

[2]  Gagnon F 1950 Contribution to the study of the etiology and prevention of cancer of the cervix of the uterus. Am J Obstet Gynecol 60 516 22


[3]  Gissmann LWL Ikenberg H Koldovsky U Schnurch HG zur Hausen H 1983 Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 80 560 3
doi:10.1073/pnas.80.2.560

[4]  Zur Hausen H 1977 Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78 1 30

[5]  Bosch F Lorincz A Munoz N Meijer C 2002 The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 244 65


[6]  Munoz N Bosch FX de Sanjose S Herrero R Castellsague X Shah KV et al 2003 International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 518 27
doi:10.1056/NEJMoa021641

[7]  Stevens MP Tabrizi SN Quinn MA Garland S 2006 Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 16 1017 24 doi:10.1111/j.1525-1438.2006.00453.x

[8]  Laverty CR Russell P Hills E Booth N 1978 The significance of non-condylomatous wart virus infection of the cervical transformation zone: a review with discussion of two illustrative ubular strictures cases. Acta Cytol 22 195 201

[9]  Hills E Laverty CR 1979 Electron microscopic detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. Acta Cytol 23 53 6


[10]  Kirnbauer R Booy F Cheng N Lowy DR Schiller J 1992 Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 12180 4
doi:10.1073/pnas.89.24.12180

[11]  Frazer IH 2010 Cervical cancer vaccine development. Sex Health 7 230 4 doi:10.1071/SH09132

[12]  Zhou J Sun XY Stenzel DJ Frazer IH 1991 Expression of vaccinia recombinant HP V 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 251 7 doi:10.1016/0042-6822(91)90772-4

[13]  Rose RC Bonnez W Reichman RC Garcea RL 1993 Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J Virol 67 1936 44

[14]  Paavonen J Naud P Salmeron J Wheeler CM Chow SN Apter DL et al 2009 Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 301 14
doi:10.1016/S0140-6736(09)61248-4

[15]  FUTURE II SG 2007 Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 1915 27 doi:10.1056/NEJMoa061741

[16]  Garland SM Hernandez AM Wheeler CM Perez G Harper DM Leodolter S et al 2007 Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 1928 43 doi:10.1056/NEJMoa061760

[17]  Paavonen J Jenkins D Bosch FX Naud P Salmerón J Wheeler CM et al 2007 Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 2161 70 doi:10.1016/S0140-6736(07)60946-5

[18]  Gertig DM Brotherton JML Saville M 2010 Methods for measuring human papillomavirus vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health doi:10.1071/SH10001 in press.

[19]  Joseph T Menzies R 2010 Human papillomavirus vaccination and Australian Indigenous women. Sex Health doi:10.1071/SH10041 in press.

[20]  Brotherton JML Kaldor JM Garland SM 2010 Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health 7 310 19 doi:10.1071/SH09137

[21]  Cooper Robbins SC Bernard D McCaffery K Skinner SR 2010 ‘It’s a logistical nightmare!’: Recommendations for optimising human papillomavirus school-based vaccination experiences. Sex Health 7 271 8 doi:10.1071/SH09140

[22]  Fairley C Hocking J Chen M Donovan B Bradshaw C 2009 Rapid decline in warts after national quadrivalent HPV vaccine program. Sex Transm Infect 85 499 502 doi:10.1136/sti.2009.037788

[23]  Fairley CK Donovan B 2010 What can surveillance of genital warts tell us? Sex Health 7 325 7 doi:10.1071/SH09145

[24]  Grulich AE Jin F Conway EL Stein AN Hocking J 2010 Cancers attributable to human papillomavirus infection. Sex Health 7 244 52 doi:10.1071/SH10020

[25]  Novakovic D Cheng ATL Cope DH Brotherton JML 2010 Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sex Health 7 253 61 doi:10.1071/SH09142

[26]  Garland SM Smith JS 2010 Human papillomavirus vaccines: current status and future prospects. Drugs 70 1079 98 doi:10.2165/10898580-000000000-00000

[27]  Nghi NQ LaMontagne SD Bingham A Rafiq M Mai LTP Lien NTP et al 2010 Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health 7 262 70 doi:10.1071/SH09123

[28]  Canfell K 2010 Models of cervical screening in the era of human papillomavirus vaccination. Sex Health 7 359 67 doi:10.1071/SH10016

[29]  Zerhouni EA 2005 Translational and clinical science – time for a new vision. N Engl J Med 353 1621 3 doi:10.1056/NEJMsb053723


Full Text PDF (261 KB) Export Citation Cited By (1)